Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna-Maria Dittrich

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
ERJ Open Research|November 16, 2022
Dual CFTR modulator therapy efficacy in the real world: lessons for the futureAnna-Maria Dittrich, Sandra Y Chuang
Klinische Padiatrie|December 10, 2024
CFTR Modulator Treatment in Children<12 Years of Age - Status Quo and ChallengesDominik Funken, Katharina Schütz, Anna-Maria Dittrich
Medizinische Klinik (Munich, Germany : 1983)|September 17, 2002
[Hypo-osmolar hyponatremia as the chief symptom in hypothyroidism]Roland Schmitt, Anna Maria Dittrich, David Groneberg, et al.
ERJ Open Research|August 5, 2025
Cystic fibrosis transmembrane conductance regulator therapy with elexacaftor/tezacaftor/ivacaftor reduces detection of hallmark cystic fibrosis pathogens in Europe: progress made but no time to slow downKatharina Schütz, Sophia T Pallenberg, Ilona Rosenboom, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 30, 2023
Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosisAnna-Maria Dittrich, Sarah Sieber, Lutz Naehrlich, et al.
NPJ Biofilms and Microbiomes|December 15, 2020
The human respiratory tract microbial community structures in healthy and cystic fibrosis infantsMarie-Madlen Pust, Lutz Wiehlmann, Colin Davenport, et al.
Plos One|October 3, 2012
IL-4 attenuates pulmonary epithelial cell-mediated suppression of T cell primingMelanie Albrecht, Markus Arnhold, Sandra Lingner, et al.
Scientific Reports|November 12, 2017
Suppression of Th17-polarized airway inflammation by rapamycinOana Joean, Anja Hueber, Felix Feller, et al.
Experimental Lung Research|May 6, 2009
Lipopolysaccharide stimulation of dendritic cells induces interleukin-10 producing allergen-specific T cells in vitro but fails to prevent allergic airway diseaseBirgit Ahrens, Tobias Freund, Ro-Dug Rha, et al.
Microbiology Spectrum|September 26, 2022
Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial MetagenomeSophia T Pallenberg, Marie-Madlen Pust, Ilona Rosenboom, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
ERJ Open Research|November 16, 2022
Dual CFTR modulator therapy efficacy in the real world: lessons for the futureAnna-Maria Dittrich, Sandra Y Chuang
Klinische Padiatrie|December 10, 2024
CFTR Modulator Treatment in Children<12 Years of Age - Status Quo and ChallengesDominik Funken, Katharina Schütz, Anna-Maria Dittrich
Medizinische Klinik (Munich, Germany : 1983)|September 17, 2002
[Hypo-osmolar hyponatremia as the chief symptom in hypothyroidism]Roland Schmitt, Anna Maria Dittrich, David Groneberg, et al.
ERJ Open Research|August 5, 2025
Cystic fibrosis transmembrane conductance regulator therapy with elexacaftor/tezacaftor/ivacaftor reduces detection of hallmark cystic fibrosis pathogens in Europe: progress made but no time to slow downKatharina Schütz, Sophia T Pallenberg, Ilona Rosenboom, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|November 30, 2023
Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosisAnna-Maria Dittrich, Sarah Sieber, Lutz Naehrlich, et al.
NPJ Biofilms and Microbiomes|December 15, 2020
The human respiratory tract microbial community structures in healthy and cystic fibrosis infantsMarie-Madlen Pust, Lutz Wiehlmann, Colin Davenport, et al.
Plos One|October 3, 2012
IL-4 attenuates pulmonary epithelial cell-mediated suppression of T cell primingMelanie Albrecht, Markus Arnhold, Sandra Lingner, et al.
Scientific Reports|November 12, 2017
Suppression of Th17-polarized airway inflammation by rapamycinOana Joean, Anja Hueber, Felix Feller, et al.
Experimental Lung Research|May 6, 2009
Lipopolysaccharide stimulation of dendritic cells induces interleukin-10 producing allergen-specific T cells in vitro but fails to prevent allergic airway diseaseBirgit Ahrens, Tobias Freund, Ro-Dug Rha, et al.
Microbiology Spectrum|September 26, 2022
Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial MetagenomeSophia T Pallenberg, Marie-Madlen Pust, Ilona Rosenboom, et al.
Pageof 8